An ultralow dose paclitaxel coated drug balloon with an outer protective sheath for peripheral arterial disease treatment

Abstract

Drug-eluting coated balloon (DCB) represents a promising therapeutic method for peripheral arterial disease (PAD) due to its advantages such as no implant permanently retained in the patient and no inflammatory...

Drug-loaded balloon with built-in NIR controlled tip-separable microneedles for long-effective arteriosclerosis treatment

“…In addition to the MN-based puncture injuries, there might be complications of tips dislodgement or vessel rupture when MNs pierced into the tissue too shallowly or too deeply. Besides, the long-acting release of PTX may have a sustained inhibitory effect on endothelial cell healing and induce thrombosis [ 43 ]. Furthermore, needle tips were scattered in tissues, leading to varied drug concentrations in tissues, which might end in regionally inconsistent therapeutic effect.…”

Research progress of drug eluting balloon in arterial circulatory system

“…Microneedle Drug Eluting Balloon, which combines a 34G micro-needle with a balloon catheter based on a specific array to better distribute the drug in the vessel wall by direct injection, but due to balloon volume limitations, the needle needs to be further improved and reduced ( 23 ). At the same time, it has been proposed that an external protective sleeve can be used on the drug balloon to prevent drug loss during administration, and it has been demonstrated by in-vitro simulated dosing tests and animal tests that this method can reduce the loading of paclitaxel on the drug balloon to 30% of the mainstream loading and transfer a large amount of paclitaxel to the vessel wall, and it can be detected throughout the 90-day animal experimental study, this technique will be expected to reduce the possibility of systemic drug toxicity due to the use of paclitaxel drug balloon ( 24 ). In recent years, due to the advantages of drug balloons in clinical practice, more and more research has been devoted to the improvement of drug balloons, which improves the accuracy of drug release and reduces the toxicity of drugs to humans.…”

Stimuli-responsive polymer-based nanosystems for cardiovascular disease theranostics

“…Drug-coated balloon (DCB) intervention plays a pivotal role in the regression of atherosclerotic CVDs. [96][97][98][99][100][101] However, this therapeutic approach is limited by inadequate drug penetration and retention within atherosclerotic lesions. [102][103][104] To address these challenges, Zhou et al developed an argininefunctionalized balloon coating poly-N-methacrylate-arginine (PMA) comprising lipophilic inducible nitric oxide synthase (iNOS)-responsive nanomotors for effective atherosclerotic CVDs treatment.…”